Needham & Company LLC reiterated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX - Free Report) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $11.00 target price on the stock.
Other research analysts have also recently issued research reports about the company. Wedbush reaffirmed an "outperform" rating and set a $7.00 price target (down previously from $10.00) on shares of TScan Therapeutics in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Wednesday.
Check Out Our Latest Stock Analysis on TCRX
TScan Therapeutics Stock Performance
Shares of NASDAQ TCRX traded down $0.25 during mid-day trading on Wednesday, reaching $3.08. 2,182,684 shares of the company's stock were exchanged, compared to its average volume of 259,768. The firm has a 50-day moving average price of $4.96 and a two-hundred day moving average price of $5.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The firm has a market capitalization of $164.38 million, a price-to-earnings ratio of -2.81 and a beta of 0.79. TScan Therapeutics has a 52 week low of $2.60 and a 52 week high of $9.69.
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. Analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.
Insider Activity at TScan Therapeutics
In other news, Director Barbara Klencke acquired 5,000 shares of the business's stock in a transaction dated Monday, September 23rd. The stock was bought at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the transaction, the director now owns 45,000 shares of the company's stock, valued at $238,050. The trade was a 12.50 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.76% of the stock is currently owned by corporate insiders.
Institutional Trading of TScan Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Great Point Partners LLC raised its holdings in shares of TScan Therapeutics by 8.0% in the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company's stock valued at $5,062,000 after acquiring an additional 75,544 shares in the last quarter. Geode Capital Management LLC raised its stake in TScan Therapeutics by 8.1% in the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company's stock valued at $4,849,000 after purchasing an additional 72,967 shares in the last quarter. Checkpoint Capital L.P. purchased a new stake in TScan Therapeutics in the third quarter valued at approximately $4,110,000. State Street Corp grew its stake in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company's stock worth $3,767,000 after buying an additional 148,414 shares in the last quarter. Finally, abrdn plc increased its holdings in shares of TScan Therapeutics by 27.2% in the 3rd quarter. abrdn plc now owns 371,655 shares of the company's stock worth $1,851,000 after buying an additional 79,511 shares during the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.
About TScan Therapeutics
(
Get Free Report)
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Read More
Before you consider TScan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.
While TScan Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
